A dilution series of mixed genomic DNA samples derived from A375 cells (BRAF V600E positive) and wild type genomic DNA were tested for BRAF V600E with or without whole genome amplification (WGA). The sensitivity of this assay was determined to be 1–2%.
The Human EGFR Pathway qBiomarker Somatic Mutation PCR Array profiled 85 mutations (x axis) in 4 FFPE cell line samples, a wild-type FFPE placenta sample control, and 9 lung adenocarcinoma FFPE tissue samples of primarily (8 out of the 9 samples) Caucasian origin with mixed gender and smoking status (samples along y axis). The array detected BRAF and KRAS mutations in the FFPE MDAMB- 231 cell line (shown as peaks), which were independently confirmed using the QIAGEN KRAS PCR Kit and Pyrosequencing. One KRAS somatic mutation and one EGFR somatic mutation were also detected in 2 FFPE lung adenocarcinoma samples.
200 ng gDNA from wild-type or cancer cell lines had 85 mutations (x axis) profiled on the Human EGFR qBiomarker Somatic Mutation PCR Array. Each detected mutation is indicated as a peak. All previously identified mutations in the EGFR pathway in these cell lines were confirmed.